Alnylam gets good news on RNAi treatment; Northwestern looks at getting nanotech into cancer nuclei;

 @DamianFierce: Using self-assembling DNA tubes, Harvard researchers plan to effectively deliver drugs to cells. News | Follow @DamianFierce

> Alnylam ($ALNY) is reporting positive Phase I results for its RNAi therapy designed to treat transthyretin-mediated amyloidoisis. Release

> A NeuroSigma subsidiary, NSVascular, has bought the patents for thin-film nitinol fabrication with an eye on its drug delivery applications. News

> Getting nanocarriers to tumors is one thing; getting them inside to deliver their payloads is another. Researchers at Northwestern University are working to get nanoparticles into the nuclei of cancer cells. Article

> Pearl Therapeutics is preparing to present positive Phase II results for PT003, a novel-formulation COPD treatment. Story

> Pulmatrix has revealed the results of preclinical tests on iSperse, an inhaled drug delivery platform that demonstrated its ability to deliver antibiotics, antibodies and other macromolecules. More